Advertisement


Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

ESMO Congress 2022

Advertisement

Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA biomarkers may help to identify patients who may benefit from enzalutamide treatment compared with active surveillance (Abstract 1385P).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We published our results from the ENACT trial just a couple of months ago in JAMA Oncology. It was an interesting trial design. It was phase two, a little over 230 patients, one to one randomization; grade group one enriched and grade group two patients. Half the patients we continue to monitor in traditional active surveillance and the other half of the patients received full dose enzalutamide, the oncolytic dose for advanced prostate cancer patients. Our primary endpoints included progression, therapeutic progression based upon moving to active intervention treatments and PSA elevations. And then we also had biopsy key data at one year and two year. The patients received in the treatment arm, open label therapy with enzalutamide for one year. What we saw was a marked decrease in positive biopsy rates and a benefit to staying on treatment, on active surveillance when taking administering enzalutamide. More patients, in other words, who did not take the enzalutamide went on to active treatments. Now I want to be perfectly clear because of some of the reaction and comments I saw from my colleagues that robust education on active surveillance is really important. But what we know is that many physicians and many patients have a difficult time staying the course of active surveillance. They go to treatment, surgery, radiation, focal therapies for a whole sundry of reasons, including PSA kinetics and concern about not doing something actively when there's cancer present. Our biomarker study looking at PAM50, luminal and basal components, as well as antigen receptor activation, as well as the Decipher score has now clearly demonstrated that we can have a prognostic benefit for patients who had high Decipher scores to know that they would go on to therapeutic progression, which was the endpoint of the ENACT trial and looking at AR amplification as well as the PAM50 luminal basal delineations, we can see, and our first author, Ashley Ross, senior author, Ted Schaeffer have clearly demonstrated that these RNA biomarkers are very informative. So as we move towards more understanding of who would be a better candidate for active surveillance versus taking a treatment, I think these will be very helpful. I look forward to additional trials where we may dose adjust with the AR blocker. We may find different ways to administer the AR blocker, perhaps intraprostatic injection or perhaps different dosing, different dose scheduling. The bottom line I think, this RNA biomarker analysis is helping us to further inform physicians and patients regarding personalized decision making and fidelity to an active surveillance protocol and avoiding active treatments that may be more morbid and more costly.

Related Videos

Breast Cancer
Survivorship

Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ovarian tissue cryopreservation in those not eligible for gamete cryopreservation); ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy; and long-term follow-up to improve the management of gynecology-related issues faced by these women.

Skin Cancer
Immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Prostate Cancer

Rahul Aggarwal, MD, on Prostate Cancer: Phase III Data on Apalutamide and Androgen Deprivation in Relapsed Disease

Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with biochemically recurrent prostate cancer. These results provide support for the intensification of ADT in this setting. (Abstract LBA63).

Breast Cancer
Immunotherapy

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).

Breast Cancer

Laurence Buisseret, MD, PhD, on Triple-Negative Breast Cancer: Chemoimmunotherapy With or Without an Anti-CD73 Antibody

Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination (Abstract LBA17).

Advertisement

Advertisement




Advertisement